Remicade Biosimilar Global Market Report 2024

The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.2 billion in 2023 to $3.99 billion in 2024 at a compound annual growth rate (CAGR) of 24.4%. The increase observed in the historical period can be attributed to factors such as the introduction of Remicade (infliximab), advancements in biotechnology, the expiry of patents for biologics, the establishment of regulatory pathways, and pressures related to healthcare costs.

The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $9.1 billion in 2028 at a compound annual growth rate (CAGR) of 22.9%. The anticipated growth in the forecast period can be attributed to factors such as patent expirations, an increasing demand for cost-effective therapies, ongoing development in the biosimilar pipeline, reimbursement policies, and market consolidation. Significant trends expected during the forecast period include the influence of physician prescribing behavior, biosimilar lifecycle management, considerations related to biosimilar naming conventions, the determination of biosimilar interchangeability, and the importance of real-world evidence in the biosimilar landscape.

The increasing incidence of autoimmune diseases is poised to drive the growth of the Remicade biosimilar market. Autoimmune diseases involve the immune system mistakenly attacking and causing damage to the body's tissues and organs. Remicade biosimilars offer an effective therapeutic option for managing symptoms and reducing inflammation associated with autoimmune diseases. Notably, reports from the City University of London in October 2021 indicated that in the UK, 4 million people, or 7%, suffered from autoimmune diseases, with over 80 identified autoimmune illnesses exhibiting an annual prevalence increase of 3–9%. Similarly, the Cleveland Clinic reported that autoimmune diseases affected 1 in 15 people in the US in July 2021, with specific conditions such as Crohn's disease, ulcerative colitis, and lupus impacting millions. This rise in autoimmune diseases is a significant driver for the Remicade biosimilar market.

The substantial increase in healthcare expenditure is a key factor contributing to the growth of the Remicade biosimilar market. Healthcare expenditure refers to the total spending on healthcare goods and services over a specific period, usually annually. Biologic drugs, including Remicade, can be costly, prompting a greater focus on cost containment and resource efficiency. Biosimilars, such as those for Remicade, offer a more cost-effective alternative to originator biologics. For instance, data from the Centers for Medicare & Medicaid Services (CMS) in June 2023 revealed that the national health expenditure (NHE) in the United States reached $4.3 trillion in 2021, accounting for 18.3% of GDP. This growing healthcare expenditure is expected to drive the Remicade biosimilar market.

Innovation in product development is a notable trend in the Remicade biosimilar market, with major companies focusing on introducing innovative products to maintain their market position. An example is Amgen Inc., a US-based biotechnology company, which launched Amjevita in January 2023. Amjevita is a biosimilar version of AbbVie's Humira, designed to be as safe and effective as the original drug. With a lower cost than Humira, Amjevita offers patients a more affordable treatment option for autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

A trend in the Remicade biosimilar market is the focus on developing biosimilars for Humira drugs, a class of medications used to treat various conditions, including arthritis. Major companies are leveraging regulatory approvals to broaden their market presence. For example, in February 2021, the U.S. FDA approved an efficacy supplement for HUMIRA (adalimumab) injection, extending its indication for pediatric patients with moderately to severely active ulcerative colitis. Additionally, in April 2023, the European Commission granted marketing authorization for a citrate-free high concentration formulation of Hyrimoz, a biosimilar of adalimumab. These regulatory approvals contribute to the growth of the Humira drug market.

In April 2022, Samsung Biologics, a South Korea-based biotechnology company, acquired Samsung Bioepis Co. Ltd. for $2.3 billion. This acquisition positions Samsung Biologics to meet the increasing demand for biosimilars, access a broader range of products, expand manufacturing capacity, and strengthen its global reach. Samsung Bioepis Co. Ltd. is a South Korea-based biopharmaceutical company specializing in producing Remicade biosimilar products.

Major companies operating in the remicade biosimilar market report are AbbVie Inc., Novartis AG, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Organon & Co., Merck And Co. Inc., Janssen Biotech Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvogen Inc., Synthon International Holding B.V., Coherus Biosciences Inc., Cardinal Health Inc., Genentech Inc., Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd., Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A.

Europe was the largest region in the remicade biosimilar market in 2023. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the remicade biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of biosimilars in the Remicade biosimilars category come in strengths of 100 mg/10 ml and 500 mg/50 ml. The 100 mg/10 ml strength indicates the amount of drug in the dosage form or a unit of the dosage form, equivalent to 100 mg per 10 ml. The applications for these biosimilars include the treatment of conditions such as ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, and plaque psoriasis. Additionally, they are used for various applications in the treatment of blood disorders and oncology diseases.

The remicade biosimilars market research report is one of a series of new reports that provides remicade biosimilars market statistics, including remicade biosimilars industry global market size, regional shares, competitors with a remicade biosimilars market share, detailed remicade biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the remicade biosimilars industry. This remicade biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The remicade biosimilar market consists of sales of inflectra, renflexis, avolsa, remsima, infimab, and avolsa. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.